公开(公告)号：US11944717B2

公开(公告)日：2024-04-02

申请号：US17477947

申请日：2021-09-17

Applicant: Tulavi Therapeutics, Inc. ,  Incept, LLC

Inventor： Corinne Bright ,  Yong Ren ,  Kenneth M. Martin ,  Farhad Khosravi ,  Amarpreet S. Sawhney

IPC: A61B17/11 ,  A61B17/00 ,  A61F2/00 ,  A61F2/02 ,  A61K9/00 ,  A61L27/18 ,  A61L27/26 ,  A61L27/52 ,  A61L31/14

CPC classification number: A61L27/26 ,  A61B17/1128 ,  A61F2/00 ,  A61F2/02 ,  A61K9/0004 ,  A61L27/18 ,  A61L27/52 ,  A61L31/14 ,  A61B2017/00526 ,  A61F2210/00 ,  A61F2210/008 ,  A61F2240/00 ,  A61F2240/001 ,  A61F2250/00 ,  A61L2400/06 ,  A61L2430/32

Abstract: Disclosed are methods, devices and materials for the in situ formation of a nerve cap and/or a nerve wrap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth.

公开(公告)号：US20210361292A1

公开(公告)日：2021-11-25

申请号：US17388327

申请日：2021-07-29

Applicant: Tulavi Therapeutics, Inc. ,  INCEPT, LLC

Inventor： Corinne Bright ,  Yong Ren ,  Ken Martin ,  Farhad Khosravi ,  Amarpreet S. Sawhney

IPC: A61B17/12 ,  A61F2/08 ,  A61F2/00 ,  A61F2/02

Abstract: Disclosed are methods, devices and materials for the in situ formation of an implant for treating a nerve. A treatment site on a nerve is positioned within a cavity defined by a form. A transformable media is introduced into the form cavity to surround the treatment site. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the treatment site. The implant may be a growth inhibiting nerve cap to inhibit neuroma formation following planned or traumatic nerve injury, a growth permissive conduit for facilitating reconnection of a severed nerve, or an anchor for stabilizing a pain management electrode with respect to a nerve. Access to the nerve treatment site may be open surgical or percutaneous.

公开(公告)号：US11890393B2

公开(公告)日：2024-02-06

申请号：US17138703

申请日：2020-12-30

Applicant: Tulavi Therapeutics, Inc. ,  Incept, LLC

Inventor： Corinne Bright ,  Yong Ren ,  Kenneth M. Martin ,  Farhad Khosravi ,  Amarpreet S. Sawhney

IPC: A61B17/11 ,  A61F2/00 ,  A61F2/02 ,  A61K9/00 ,  A61L27/52 ,  A61L31/14 ,  A61B17/00 ,  A61L27/26 ,  A61L27/18

CPC classification number: A61L27/26 ,  A61B17/1128 ,  A61F2/00 ,  A61F2/02 ,  A61K9/0004 ,  A61L27/18 ,  A61L27/52 ,  A61L31/14 ,  A61B2017/00526 ,  A61F2210/00 ,  A61F2210/008 ,  A61F2240/00 ,  A61F2240/001 ,  A61F2250/00 ,  A61L2400/06 ,  A61L2430/32

Abstract: Disclosed are methods, devices and materials for the in situ formation of a nerve cap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth.

公开(公告)号：US20220054705A1

公开(公告)日：2022-02-24

申请号：US17477947

申请日：2021-09-17

Applicant: Tulavi Therapeutics, Inc. ,  Incept, LLC

Inventor： Corinne Bright ,  Yong Ren ,  Kenneth M. Martin ,  Farhad Khosravi ,  Amarpreet S. Sawhney

IPC: A61L27/26 ,  A61B17/11 ,  A61F2/00 ,  A61F2/02 ,  A61K9/00 ,  A61L27/18 ,  A61L27/52 ,  A61L31/14

Abstract: Disclosed are methods, devices and materials for the in situ formation of a nerve cap and/or a nerve wrap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth

公开(公告)号：US12096941B2

公开(公告)日：2024-09-24

申请号：US17388327

申请日：2021-07-29

Applicant: Tulavi Therapeutics, Inc. ,  INCEPT, LLC

Inventor： Corinne Bright ,  Yong Ren ,  Ken Martin ,  Farhad Khosravi ,  Amarpreet S. Sawhney

IPC: A61B17/12 ,  A61F2/00 ,  A61F2/02 ,  A61F2/08 ,  A61L27/52

CPC classification number: A61B17/12181 ,  A61F2/0059 ,  A61F2/02 ,  A61F2/08 ,  A61L27/52

Abstract: Disclosed are methods, devices and materials for the in situ formation of an implant for treating a nerve. A treatment site on a nerve is positioned within a cavity defined by a form. A transformable media is introduced into the form cavity to surround the treatment site. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the treatment site. The implant may be a growth inhibiting nerve cap to inhibit neuroma formation following planned or traumatic nerve injury, a growth permissive conduit for facilitating reconnection of a severed nerve, or an anchor for stabilizing a pain management electrode with respect to a nerve. Access to the nerve treatment site may be open surgical or percutaneous.

公开(公告)号：US20220096711A1

公开(公告)日：2022-03-31

申请号：US17547583

申请日：2021-12-10

Applicant: Tulavi Therapeutics, Inc. ,  Incept, LLC

Inventor： Corinne Bright ,  Yong Ren ,  Kenneth M. Martin ,  Farhad Khosravi ,  Amarpreet S. Sawhney

IPC: A61L27/26 ,  A61B17/11 ,  A61F2/00 ,  A61F2/02 ,  A61K9/00 ,  A61L27/18 ,  A61L27/52 ,  A61L31/14

Abstract: Disclosed are methods, devices and materials for the in situ formation of a nerve cap and/or a nerve wrap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth

公开(公告)号：US20210315587A1

公开(公告)日：2021-10-14

申请号：US17148427

申请日：2021-01-13

Applicant: Tulavi Therapeutics, Inc. ,  INCEPT, LLC

Inventor： Corinne Bright ,  Yong Ren ,  Ken Martin ,  Farhad Khosravi ,  Amarpreet S. Sawhney

IPC: A61B17/12 ,  A61F2/08 ,  A61F2/00 ,  A61F2/02

Abstract: Disclosed are methods, devices and materials for the in situ formation of an implant for treating a nerve. A treatment site on a nerve is positioned within a cavity defined by a form. A transformable media is introduced into the form cavity to surround the treatment site. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the treatment site. A hydrophilic characteristic of the media cooperates with a hydrophobic characteristic of the surface of the cavity to facilitate a rapid release of the implant from the cavity following the transformation. The implant may be a growth inhibiting nerve cap to inhibit neuroma formation following planned or traumatic nerve injury, a growth permissive conduit for facilitating reconnection of a severed nerve, or an anchor for stabilizing a pain management electrode with respect to a nerve. Access to the nerve treatment site may be open surgical or percutaneous.

公开(公告)号：US12171869B2

公开(公告)日：2024-12-24

申请号：US15714633

申请日：2017-09-25

Applicant: Incept, LLC.

Inventor： Amarpreet S. Sawhney ,  Arthur Driscoll ,  Charles D. Blizzard ,  Ankita D. Desai ,  Peter Jarrett

IPC: A61K9/00 ,  A61F9/00 ,  A61F9/007 ,  A61K9/16 ,  A61K47/10 ,  A61K31/382 ,  A61K31/40 ,  A61K47/34

Abstract: Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel after exposure to intraocular fluid and is degradable. The degradable particles comprise the therapeutic agent and hydrolytically degrade in the anterior chamber to provide a controlled release of the therapeutic agent into the eye. Materials and processes for making depots are provided as well as alternative methods of their use.

公开(公告)号：US20220370419A1

公开(公告)日：2022-11-24

申请号：US17830968

申请日：2022-06-02

Applicant: Incept, LLC

Inventor： Peter Jarrett ,  Rami El-Hayek ,  Timothy S. Jarrett ,  Charles D. Blizzard ,  Amarpreet S. Sawhney

IPC: A61K31/436 ,  A61K31/44 ,  A61K31/404 ,  A61K31/502 ,  A61K31/496 ,  A61K31/56 ,  A61K31/517 ,  A61K31/444 ,  A61K9/00

Abstract: Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed in the hydrogel, the agent having a low solubility in water. The agent may be essentially insoluble in water. The hydrogel may be made so that 50% to 100% w/w of the agent is released when the hydrogel is from 100% to 50% persistent, with the persistence being a measure of the dry weight of the hydrogel relative to an initial dry weight of the hydrogel.

公开(公告)号：US11160883B2

公开(公告)日：2021-11-02

申请号：US16817297

申请日：2020-03-12

Applicant: Incept, LLC

Inventor： Patrick Campbell ,  Amarpreet S. Sawhney

IPC: A61K49/04 ,  A61K51/12 ,  A61L27/50 ,  A61L27/52 ,  A61L27/58 ,  A61L31/14 ,  A61L31/18

Abstract: Implantable materials visible under ultrasound may be delivered to a selected placement site and biodegrade after a certain period of time. Ultrasound visible implantable materials may be delivered through an applicator and may include ultrasound contrast agents and/or radiopaque agents. Applications include monitoring the delivery of an implant of the implantable materials to the placement site with ultrasound and delivery of therapeutic agents to a tissue at the placement site for treating a patient.